How to Manage Patients with Differentiated Thyroid Cancer and a Rising Serum Thyroglobulin Level

• Autores: Rossella Elisei, Laura Agate, David Viola, Antonio Matrone, Agnese Biagini, Eleonora Molinaro
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 43, Nº. 2, 2014 (Ejemplar dedicado a: Thyroid Cancer and Other Thyroid Disorders), págs. 331-344
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Serum thyroglobulin (sTg) is the marker for monitoring persistence/recurrence of differentiated thyroid cancer, in patients without sTg antibodies. Patients with undetectable basal sTg or peak sTg <2 ng/mL are cured with low risk to recur. Newly detectable level of sTg indicates the recurrence. The significance of increasing sTg in patients treated with emithyroidectomy or total-thyroidectomy but not ablated with radioiodine is undefined. A doubling time <1 year may be a poor prognostic factor, but this is more relevant in cases with high levels of sTg. Because of its sensitivity, neck ultrasound should be performed at any visit, especially when an increased sTg is seen.